Imbio PHA (4.0.0) vs Viz HCM
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is automated, quantitative analysis of cardiac structures from CT pulmonary angiogram (CTPA) scans. This tool is ideal for rapidly assessing right ventricular dilation and aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension, providing precise measurements and detailed reports.
View Imbio PHA (4.0.0) →Choose Viz HCM if…
Choose Viz HCM if your focus is on real-time, AI-powered detection of suspected Hypertrophic Cardiomyopathy (HCM) directly from ECG analysis. This solution is best suited for healthcare systems aiming to significantly reduce HCM diagnosis time and streamline the coordination of cardiac care through immediate alerts and automated patient routing.
View Viz HCM →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | Viz HCM |
|---|---|---|
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Unknown |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz HCMViz HCM's emphasis on real-time ECG analysis, mobile-based alerts, and automated care coordination suggests a more dynamic and broadly accessible user experience for multidisciplinary teams. Imbio PHA, while integrating with existing radiology workflows, focuses primarily on image processing and reporting.
Clinical Value
Viz HCMViz HCM explicitly highlights 'significantly reducing diagnosis time' and states it is 'clinically validated with extensive real-world evidence and publications'. Imbio PHA aids in diagnosis and risk stratification but does not provide the same level of explicit impact or validation claims in the provided data.
Pricing & Value
Viz HCMViz HCM offers greater transparency with its subscription-based model and explicitly mentions CMS reimbursement availability for specific CPT codes, providing clear financial value to healthcare providers. Imbio PHA's pricing information is only available upon contact, offering less transparency.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers flexible deployment options including 'Cloud, Enterprise (on-premise), or via partners,' which provides more versatility for large institutions with specific infrastructure or data governance requirements. Both tools are FDA-cleared and HIPAA compliant.
Innovation
Viz HCMViz HCM's approach to real-time ECG analysis for HCM detection, combined with mobile alerts and automated care coordination, represents a more comprehensive and proactive application of AI in the clinical workflow. Imbio PHA's automated measurement of cardiac structures from CTPA is innovative but more focused on diagnostic assistance.
Support & Docs
Viz HCMViz.ai provides a robust support ecosystem, including a comprehensive 'Help Center' and 'Knowledge Base,' 24/7 urgent phone support, and 'Viz Academy'. Imbio offers standard contact support and documentation, with user manuals available upon request or found online for other products.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | Viz HCM |
|---|---|---|
| Product Name | Imbio PHA (4.0.0) | Viz HCM |
| Company | Imbio | Viz.ai |
| Description | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | FDA-cleared AI tool by Viz.ai that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and coordinate cardiac care, significantly reducing diagnosis time. |
| Primary Focus | Pulmonary embolism and hypertension assessment from CTPA scans | Hypertrophic Cardiomyopathy (HCM) detection from ECG analysis |
| Key Features (Example 1) | Automated measurement of right and left ventricle diameters | AI-powered ECG analysis for Hypertrophic Cardiomyopathy (HCM) detection |
| Key Features (Example 2) | Generates annotated DICOM images | Mobile-based alerts and notifications to multidisciplinary care teams |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Viz HCM.